TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12427067

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at closer distance (2 m)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at 10 ft
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at 3.2 m
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (VA) scores at closer distance (2 m) censored
Number of subjects: 4
Study: 10489797

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 12885

Group type: COMPARATOR
Intervention: Control group (non-cannabis users)
Number of subjects: 12885
Study: 7492463

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study: 2291866

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7389323

Group type: EXPERIMENTAL
Intervention: Topical idoxuridine 0.5% and 5% in petrolatum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical idoxuridine 5‐40% in dimethylsulfoxide (previous treatment)
Number of subjects: 60
Study: 30334154

Group type: EXPERIMENTAL
Intervention: Temporary simultaneous two‐arterial occlusions (TESTO)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 28193399

Group type: EXPERIMENTAL
Intervention: Resource centre intervention
Number of subjects: 12614
Study: 25899550

Group type: EXPERIMENTAL
Intervention: Quantitative pretest probability (qPTP) for ACS and PE with advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (no qPTP and no advice)
Number of subjects: 0
Study: 24954134

Group type: EXPERIMENTAL
Intervention: 5% green tea mouthwash
Number of subjects: 97

Group type: COMPARATOR
Intervention: 0.12% CHX mouth rinse
Number of subjects: 97
Study: 21917635

Group type: EXPERIMENTAL
Intervention: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled casein protein (PRO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 19116389

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of ascorbic acid daily)
Number of subjects: 7627

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU of alpha-tocopherol every other day)
Number of subjects: 7627

Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg every other day)
Number of subjects: 7627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7627
Study: 17324218

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICMs) with 0.6 microg/ml epinephrine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intracameral mydriatics (ICMs) without epinephrine
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Topical mydriatics (TMs) with 0.6 microg/ml epinephrine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Topical mydriatics (TMs) without epinephrine
Number of subjects: 140
Study: 14717965

Group type: EXPERIMENTAL
Intervention: SanOrg34006 2.5 mg
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: SanOrg34006 (5.0, 7.5, 10 mg)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Warfarin (INR, 2.0-3.0)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: SanOrg34006 (all doses)
Number of subjects: 659
Study: 11749654

Group type: EXPERIMENTAL
Intervention: 8-week exercise training programme
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual lifestyle control group
Number of subjects: 21
Study: 9675647

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxycillin 1000 mg b.i.d. for one week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg b.i.d. for one week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pre-treatment Delta Over Baseline at 30' value
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pre- and post-treatment Delta Over Baseline at 30' values
Number of subjects: 108
Study: 7516297

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 10
Study: 2913551

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-term follow-up)
Number of subjects: 21
Study: 1101619

Group type: EXPERIMENTAL
Intervention: Etidocaine 1 %
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5 %
Number of subjects: 0
Study: 31790704

Group type: COMPARATOR
Intervention: Computational genomic analysis of purine-pyrimidine sequences in selected genomes
Number of subjects: 3

Group type: COMPARATOR
Intervention: Computational genomic analysis of hydrogen-bond-based HIDERs
Number of subjects: 3
Study: 31053537

Group type: EXPERIMENTAL
Intervention: Community-onset Acinetobacter species pneumonia (AP)
Number of subjects: 13
Study: 28453340

Group type: EXPERIMENTAL
Intervention: ChloraPrep
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: DuraPrep
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Betadine
Number of subjects: 240
Study: 25388940

Group type: EXPERIMENTAL
Intervention: CT-322 monotherapy at 1 mg/kg IV weekly
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CT-322 monotherapy at 2 mg/kg IV weekly
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CT-322 + irinotecan IV semiweekly
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 23596812

Group type: EXPERIMENTAL
Intervention: Fuzhengliqi mixture (FLM) 60 mL twice a day
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Dachangshu (BL 25), and Zhigou (TE 6) twice a day
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Combined therapy with FLM and acupuncture
Number of subjects: 560

Group type: COMPARATOR
Intervention: Mosapride (5 mg thrice a day) and Macrogol 4000 (10 g twice a day)
Number of subjects: 560
Study: 21660772

Group type: EXPERIMENTAL
Intervention: Single intervention session to teach empirically valid self‐directed weight‐control methods
Number of subjects: 66

Group type: COMPARATOR
Intervention: Assessment‐only control condition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Self-weighing frequency
Number of subjects: 66
Study: 19349340

Group type: EXPERIMENTAL
Intervention: Community-based rehabilitation therapy for five months
Number of subjects: 737

Group type: COMPARATOR
Intervention: Control group (no additional rehabilitation therapy)
Number of subjects: 737
Study: 16193299

Group type: EXPERIMENTAL
Intervention: 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1,000 mg of oral calcium daily (groups IB, IIB, IIIB)
Number of subjects: 110
Study: 15130257

Group type: EXPERIMENTAL
Intervention: Doxycycline therapy (100 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Inpatient and outpatient treatment groups
Number of subjects: 91
Study: 11524318

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol Bolus followed by Isoflurane
Number of subjects: 0
Study: 9239772

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: COMVAX (Hib and hepatitis B vaccine)
Number of subjects: 295
Study: 8512675

Group type: EXPERIMENTAL
Intervention: Exercise testing using the Schwade Arm Ergometer Protocol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comparison of achieved values with baseline (pre-exercise) values
Number of subjects: 64
Study: 2962417

Group type: EXPERIMENTAL
Intervention: M‐DSG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T‐GSD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: T‐LNG
Number of subjects: 60
Study: 29692602

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg) alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg) plus Ezetimibe (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 28715142

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg, 3 times/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25240140

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Short Psychodynamic Supportive Psychotherapy (SPSP)
Number of subjects: 341
Study: 22899814

Group type: EXPERIMENTAL
Intervention: Chronic NaHCO3 ingestion (ALK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 21995692

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe 10/10 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study: 18466210

Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Four daily insulin injections
Number of subjects: 38
Study: 17144454

Group type: EXPERIMENTAL
Intervention: PYM emulsion applied 3 times daily on the lesions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with only matrix applied
Number of subjects: 30
Study: 12725542

Group type: EXPERIMENTAL
Intervention: Once-daily (OD) gentamicin 5 mg kg(‐1) d(‐1)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional 8-hourly dosing (TDS) gentamicin 6 mg kg(‐1) d(‐1)
Number of subjects: 172
Study: 10697444

Group type: EXPERIMENTAL
Intervention: Community pharmacy based programme for therapeutic outcomes monitoring
Number of subjects: 500
Study: 9109868

Group type: EXPERIMENTAL
Intervention: MRI of the forearm in IBM patients
Number of subjects: 30
Study: 1585841

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 273

Group type: COMPARATOR
Intervention: Comparison group (no nicotine gum)
Number of subjects: 273
Study: 3995516

Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg ISDSR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two doses of 40 mg ISDSR (at 07.30 and 13.30 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31250602

Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure therapy (20 minutes, 5 times per week for 4 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no recovery intervention)
Number of subjects: 14
Study: 29700480

Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 528

Group type: COMPARATOR
Intervention: Antibiotic group
Number of subjects: 528
Study: 26808136

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg or 100 mg daily)
Number of subjects: 2173

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2173
Study: 24471665

Group type: EXPERIMENTAL
Intervention: CVVHDF with catheter tip at right atrium
Number of subjects: 94

Group type: COMPARATOR
Intervention: CVVHDF with catheter tip at superior vena cava
Number of subjects: 94
Study: 22742538

Group type: EXPERIMENTAL
Intervention: Immediate antibiotic therapy with fosfomycin-trometamol 1x3g
Number of subjects: 494

Group type: COMPARATOR
Intervention: Initial symptomatic treatment with ibuprofen 3x400mg for 3 days
Number of subjects: 494
Study: 21063142

Group type: EXPERIMENTAL
Intervention: Limited intraoperative hydration (no more than 1500 ml in the first 2 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No hydration intervention (control group)
Number of subjects: 15
Study: 17560512

Group type: EXPERIMENTAL
Intervention: (18)F FDG PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel imaging techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advances in molecular imaging
Number of subjects: 0
Study: 16279901

Group type: EXPERIMENTAL
Intervention: Sequential therapy with lamivudine 100 mg per day for 52 weeks and IFN 5 MIU per day for 16 weeks after the first 8 weeks (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lamivudine monotherapy 100 mg per day for 52 weeks (group B)
Number of subjects: 75
Study: 16885196

Group type: COMPARATOR
Intervention: TNFA (‐308 G>A) polymorphism
Number of subjects: 305

Group type: COMPARATOR
Intervention: IFNGR2 Ex7‐128 C>T polymorphism
Number of subjects: 305

Group type: COMPARATOR
Intervention: Combination of IFNGR2 Ex7‐128 C/C and TNFA ‐308 A/A genotypes
Number of subjects: 305

Group type: COMPARATOR
Intervention: IL1A (‐889 C>T) and IL12A variants
Number of subjects: 305
Study: 11236850

Group type: EXPERIMENTAL
Intervention: HUI3
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HUI3 and EQ-5D
Number of subjects: 88
Study: 8867523

Group type: EXPERIMENTAL
Intervention: Enadoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen-codeine combination
Number of subjects: 0
Study: 1507326

Group type: EXPERIMENTAL
Intervention: Piezoelectric extracorporeal shock wave lithotripsy (ESWL) retreatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 50
Study: 6388070

Group type: EXPERIMENTAL
Intervention: anti-T3 antibody (5 mg i.v./day for 14 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: steroid treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: anti-T3 antibody
Number of subjects: 18
Study: 29595751

Group type: EXPERIMENTAL
Intervention: Additional information provided at the invitation for routine screening
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Additional information provided after detection of cellular abnormalities
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Additional information provided for recommended precancer treatment
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 1060
Study: 30281402

Group type: EXPERIMENTAL
Intervention: Giving motivational advice to younger students
Number of subjects: 2274

Group type: COMPARATOR
Intervention: Receiving motivational advice from expert teachers
Number of subjects: 2274

Group type: EXPERIMENTAL
Intervention: Giving advice
Number of subjects: 2274

Group type: COMPARATOR
Intervention: Receiving expert advice
Number of subjects: 2274
Study: 27075143

Group type: EXPERIMENTAL
Intervention: Music via speakers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Music via headphones
Number of subjects: 30

Group type: COMPARATOR
Intervention: No music
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison between speakers and headphones
Number of subjects: 30

Group type: COMPARATOR
Intervention: Initial assignment of speakers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Initial assignment of headphones
Number of subjects: 30
Study: 24707787

Group type: EXPERIMENTAL
Intervention: Goal-driven regulation of study effort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data-driven regulation of study effort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of study time interpretation
Number of subjects: 0
Study: 22167563

Group type: EXPERIMENTAL
Intervention: Romiplostim (subcutaneous, dose range 0.2‐10 µg/kg)
Number of subjects: 52
Study: 20427630

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 606

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 606
Study: 17905315

Group type: EXPERIMENTAL
Intervention: Office chair with a motor‐driven seat performing a horizontal rotary movement
Number of subjects: 280

Group type: COMPARATOR
Intervention: Chair of the same design without the rotary seat movement
Number of subjects: 280
Study: 15691277

Group type: EXPERIMENTAL
Intervention: ATG induction therapy
Number of subjects: 84
Study: 12019929

Group type: EXPERIMENTAL
Intervention: Dietary advice to reduce sodium intake for 2 weeks
Number of subjects: 82
Study: 10721643

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg thrice a day for three days, starting one hour prior to angiography)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (routine angiography without captopril)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg thrice a day for three days)
Number of subjects: 71
Study: 7537489

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 142
Study: 31045329

Group type: EXPERIMENTAL
Intervention: WinFood Classic (WFC)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: WinFood Lite (WFL)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Fortified corn-soy blend plus (CSB+)
Number of subjects: 499
Study: 28451442

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single steroid injection (followed by later surgery if required)
Number of subjects: 0
Study: 24958769

Group type: EXPERIMENTAL
Intervention: RESPOND intervention
Number of subjects: 528

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 528
Study: 23324512

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (complete medication history, limited physical examination, provision of guideline-concordant recommendations, and 1-year follow-up)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care without pharmacist interactions (Control)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 136
Study: 21401833

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/active comparator
Number of subjects: 0
Study: 18381837

Group type: EXPERIMENTAL
Intervention: BE-ACTIV intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 20
Study: 16096994

Group type: EXPERIMENTAL
Intervention: Panic disorder (PD) diagnosis based on DSM-IV criteria
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Subthreshold panic disorder
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Telephone interviews for epidemiological surveys
Number of subjects: 3004
Study: 12880499

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of sertraline and CBT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 120
Study: 10642897

Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation (one tablet daily for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study: 8895156

Group type: EXPERIMENTAL
Intervention: N‐3 fatty acids (fish oil) 8 g for 16 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 100
Study: 1856908

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6828277

Group type: EXPERIMENTAL
Intervention: Ampicillin (2-g dose administered intravenously)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to ampicillin)
Number of subjects: 71
Study: 30121944

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) treatment for 3 weeks during neonatal care
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 34
Study: 30293225

Group type: EXPERIMENTAL
Intervention: Long CCI (≥ 1.75 mm)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Short CCI (< 1.75 mm)
Number of subjects: 128
Study: 27306517

Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum and pemetrexed) in combination with erlotinib
Number of subjects: 3

Group type: COMPARATOR
Intervention: EGFR-TKIs
Number of subjects: 3
Study: 25207513

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Self-monitoring weight
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Gym attendance/participating in exercise classes
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Eating less fat
Number of subjects: 404
Study: 22947843

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hand instrumentation (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control group, n=10)
Number of subjects: 30
Study: 21050497

Group type: EXPERIMENTAL
Intervention: 15 hour face-to-face educational intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 18787352

Group type: COMPARATOR
Intervention: Weekly docetaxel (DOC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Weekly vinorelbine (VIN)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Crossover treatment (X-DOC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Crossover treatment (X-VIN)
Number of subjects: 122
Study: 16004670

Group type: EXPERIMENTAL
Intervention: CC plus HS (Clomiphene Citrate plus Hormone Supplementation)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No HS (Clomiphene Citrate alone)
Number of subjects: 71
Study: 12445222

Group type: EXPERIMENTAL
Intervention: One-stage procedure (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-stage procedure (n = 20)
Number of subjects: 40
Study: 10522715

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping (LM) with blue dye plus radiocolloid
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Lymphatic mapping (LM) with blue dye alone
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Sentinel node (SN) identification in MSLT group after learning phase
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Incidence of nodal metastases in MSLT group
Number of subjects: 1135
Study: 7795283

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily, every other day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Omeprazole (weekend regimen)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Omeprazole (every other day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Ranitidine (150 mg nocte)
Number of subjects: 140